When Is It Best to Fracture a Bioprosthesis in TAVR?

At present, surgical aortic valve replacement (SAVR) uses bioprostheses. However, when these fail, we are presented with a great challenge, seeing as repeat SAVR involves a higher risk. In this context, valve-in-valve (V-in-V TAVR) has surged as a very attractive alternative. 

¿Cuándo es el mejor momento para realizar una fractura de la bioprótesis en el TAVI?

Bioprosthesis fracture (BPF) is a new interesting strategy that has shown lower gradient and larger effective orifice area (especially in small valves). However, it still involves certain risk. 

This analysis looked at STS/ACC registry V-in-V patients treated with SAPIEN 3 or SAPIEN ULTRA undergoing BPF before or after V-in-V TAVR. 

2975 patients were included, and 619 received BPF before or after TAVR (20.8%).

There were no differences between groups. Mean age was 73, 70% were men, 82% were hypertensive, 32% diabetic, 14% had prior pacemaker, and 65 ml/min eGFR. Prior CABG, cardiac failure and cardiogenic shock was higher among patients not receiving BPF. 

STS Score was 5.3%.

Read also: Left Main Coronary Artery Revascularization: Are Periprocedural Complications Significant?

95% pr procedures were transfemoral, implantation success rate was 99%, and SAPIEN 3 was used most often (84%).

BPF was more frequent after TAVR (75%); 23% was done before TAVR and 2% before and after TAVR. BPF was successful in 512 patients (83%), and it was more frequent in patients with 21 mm bioprosthesis (30% vs.15% p<0.01).

At hospital level, patients receiving BPF presented higher all-cause mortality (2.26 0.91 2.51 1.3-4.84 p<0.01) and life threatening bleeding 3.39 (1.36 2.55 (1.44-4.5) <0.01), with no differences as regards vascular complications, stroke, definite pacemaker implantation, atrial fibrillation, heart obstruction, ring fracture, dialysis, aortic dissection and cardiac piercing. 

Read also: Survival in Patients with Tricuspid Regurgitation According to Clinical and Echocardiographic Variables (Clusters).

At 30 days, hemodynamic assessment was carried out by Eco-Doppler, which showed that when BPF was prior V-in-V there were no hemodynamic differences vs. the rest. However, in post V-in-V BPF patients, there was larger effective orifice area (1.6 cm2 vs 1.4 cm2; P < 0.01) and lower gradient (18.3 mm Hg vs 22.6 mm Hg; P < 0.01). 

Conclusion

Bioprosthesis fracture in V-in-V with SAPIEN 3 or SAPIEN ULTRA was associated to high inhospital mortality and bleeding and modest echocardiographic hemodynamic improvement. Appropriate bioprosthesis fracture timing is associated to safety and efficacy. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Outcomes of Bioprosthetic Valve  Fracture in Patients Undergoing Valve-in-Valve TAVR. 

Reference: Adnan K. Chhatriwalla, et al. J Am Coll Cardiol Intv 2023;16:530–539).


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...